Caprock Mining Corp

Capricor Therapeutics submitted a Biologics License Application to the FDA for deramiocel, a potential first therapy for Duchenne muscular dystrophy cardiomyopathy. The submission, supported by clinical trial data, could lead to a $10 million milestone payment from Nippon Shinyaku. Deramiocel has shown promise in attenuating DMD's cardiac effects.

Capricor Therapeutics completed its BLA submission to the FDA for deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy, supported by Phase 2 trial data. It seeks a priority review to shorten the FDA's review timeline from 10 to 6 months.

Capricor Therapeutics submitted a Biologics License Application to the FDA for deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy, potentially the first approved therapy for this condition. The company's stock surged 192% in six months, reflecting investor optimism. Capricor seeks a priority review, which could shorten the FDA's review period to six months, and is set to receive a $10 million payment from its distribution partner, Nippon Shinyaku. Deramiocel has shown promise in managing DMD's cardiac complications, with over 200 patients treated in clinical studies.

Capricor Therapeutics submitted a Biologics License Application to the FDA for deramiocel, targeting Duchenne muscular dystrophy cardiomyopathy, triggering a $10M milestone payment from Nippon Shinyaku. The submission includes Phase 2 trial data, seeking priority review. Deramiocel offers potential immunomodulatory and regenerative benefits for DMD patients.

Capricor Therapeutics submitted a BLA to the FDA for deramiocel, a potential first therapy for DMD cardiomyopathy, triggering a $10M milestone payment from Nippon Shinyaku.

Deramiocel (CAP-1002), derived from cardiosphere-derived cells (CDCs), offers therapeutic potential for Duchenne muscular dystrophy (DMD) through immunomodulatory, anti-inflammatory, pro-angiogenic, and anti-fibrotic actions. Its efficacy is mediated by exosomes containing bioactive microRNAs, altering gene expression to reduce inflammation and stimulate tissue regeneration. Ongoing research explores its expanded use and synergy with emerging therapies.